Vanguard Group’s Novo Nordisk NVO Stock Holding History

Vanguard Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-28,800	Closed	-$789K	–	4198
2015 Q2	$789K	Sell	28,800 -70,400	-71%	-$1.98M	﹤0.01%	3737
2015 Q1	$2.65M	Buy	+99,200	New	+$2.28M	﹤0.01%	3292

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Vanguard Group's NVO Position: Q3 2015 in Review

Vanguard Group sold out of Novo Nordisk (NVO) in Q3 2015, closing a stake of 28,800 shares — an estimated $789K sold.

Vanguard Group first reported a position in NVO in Q1 2015 and held it in 2 quarters. The position peaked at $2.65M in Q1 2015. 525 funds tracked by Wall St. Rank hold NVO as of Q3 2015.

Vanguard Group reported no remaining Novo Nordisk position as of Q3 2015 after selling out during the quarter.
Vanguard Group sold 28,800 Novo Nordisk shares in Q3 2015, an estimated $789K.
Vanguard Group first reported a position in Novo Nordisk in Q1 2015 and held it in 2 quarters.
Vanguard Group's Novo Nordisk position peaked at $2.65M in Q1 2015.
525 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2015.

Based on Vanguard Group's 13F filing for Q3 2015, filed 12 Nov 2015.